Overview
On July 21, 2026, in Hyderabad, Apollo Hospitals Enterprise Ltd announced a strategic collaboration with the American biotech firm Precisio Biotix Therapeutics Inc. to accelerate the development and clinical adoption of lysin‑based antimicrobials in India. The partnership will concentrate on translational research, clinical validation, and the creation of deployment pathways for lysin therapies across Apollo’s extensive network, targeting infectious diseases where current treatment options are limited.
Lysins are described as next‑generation precision antimicrobials—cell‑wall hydrolase enzymes that act rapidly, disrupt biofilms, and selectively target pathogens without contributing to antimicrobial resistance, unlike conventional antibiotics.
Dr Sangita Reddy, Joint Managing Director of Apollo Hospitals Enterprise Ltd, stated that antimicrobial resistance (AMR) is one of the most urgent and complex challenges facing modern healthcare and emphasized Apollo’s commitment to precision‑medicine approaches that go beyond conventional therapies. She highlighted that the collaboration represents a shift toward biology‑led solutions that can preserve the effectiveness of existing treatments.
The collaboration will produce a white paper on lysin‑based therapies and AMR management in India and will implement compassionate‑use/expanded‑access clinical programs, including those for prosthetic joint infections.
Mark Engel, Founder & CEO of Precisio Biotix, remarked that Apollo’s clinicians are among the best in Asia for treating difficult antibiotic‑resistant patients and that Precisio’s novel lysin products target and rapidly break bacterial cell walls, killing identified pathogens without disturbing the healthy microbiota or fostering resistance.
About Apollo Hospitals
Apollo Hospitals Enterprise Ltd, founded by Dr Prathap Reddy in 1983, has grown into the world’s largest integrated healthcare platform with more than 10,400 beds across 76 hospitals, over 6,600 pharmacies, 264 clinics, 2,182 diagnostic centres, and 800+ telemedicine centres. It is a leading cardiac centre, having performed over 300,000 angioplasties and 200,000 surgeries, and employs approximately 120,000 family members dedicated to delivering exceptional care.
About Precisio Biotix Therapeutics Inc.
Precisio Biotix is an American biotechnology company developing lower‑cost, precision‑engineered biological antibacterials, initially focusing on respiratory, skin, and prosthetic joint infections. It operates as a platform‑plus‑product company with both prescription (Rx) and consumer offerings and maintains R&D operations in India, China, and the United Kingdom. The management team has completed multiple successful exits and is currently seeking strategic partners for all aspects of the business.
Disclaimer: This press release is provided under an arrangement with PRNewswire; PTI assumes no editorial responsibility.